Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26982015 | 0.90 | MAPT (0.43) | USP30HTTNPSR1MAPTHDAC2 | |
| SCHEMBL29116459 | 0.85 | MAPT (0.40) | USP30SMN1; SMN2MAPTALDH1A1THRB | |
| SCHEMBL26981966 | 0.80 | USP30 (0.42) | USP30HTTSMN1; SMN2NPSR1MAPT | |
| SCHEMBL21778061 | 0.79 | SMN1; SMN2 (0.50) | HTTSMN1; SMN2NPSR1MAPTALDH1A1 | |
| SCHEMBL26981939 | 0.76 | NPSR1 (0.48) | HTTSMN1; SMN2NPSR1MAPTALDH1A1 | |
| SCHEMBL21778012 | 0.73 | SMN1; SMN2 (0.49) | HTTSMN1; SMN2NPSR1MAPTHDAC1 | |
| SCHEMBL17605822 | 0.73 | DNMT3A (0.44) | HTTSMN1; SMN2NPSR1MAPTHDAC2 | |
| SCHEMBL26981970 | 0.72 | MAPT (0.40) | HTTSMN1; SMN2NPSR1MAPTGPR119 | |
| SCHEMBL30069764 | 0.72 | ALDH1A1 (0.41) | HTTSMN1; SMN2NPSR1GPR119ALDH1A1 | |
| SCHEMBL26981951 | 0.72 | ALDH1A1 (0.41) | HTTSMN1; SMN2NPSR1GPR119ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725486-A2 | CRYSTALLINE FORMS OF 5-(3,4-DIFLUOROBENZYL)-8-((1R,4R)-4-METHYLCYCLOHEXYL)-6,9-DIOXO-2,5,8-TRIAZASPIRO[3.5]NONANE-2-CARBALDEHYDE | Cytokinetics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12286437-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20240309011-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240132498-A1 | CRYSTALLINE FORMS OF 5-(3,4-DIFLUOROBENZYL)-8-((1R,4R)-4-METHYLCYCLOHEXYL)-6,9-DIOXO-2,5,8-TRIAZASPIRO[3.5]NONANE-2-CARBALDEHYDE | CYTOKINETICS, INCORPORATED | 2024-04-25 | — | — | US | disclosed |
| WO-2024050539-A1 | CRYSTALLINE FORMS OF 5-(3,4-DIFLUOROBENZYL)-8-((1R,4R)-4-METHYLCYCLOHEXYL)-6,9-DIOXO-2,5,8-TRIAZASPIRO[3.5]NONANE-2-CARBALDEHYDE | CYTOKINETICS, INCORPORATED (US) | 2024-03-07 | — | — | WO | disclosed |
| US-11919909-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-4301760-A1 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20220306642-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2022-09-29 | — | — | US | disclosed |
| WO-2022187501-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919909-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, TNNC1 | USP30 2511/4885HTT 1314/4885SMN1; SMN2 101/4885 |
| US-12286437-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, TNNC1 | USP30 2511/4885HTT 1314/4885SMN1; SMN2 101/4885 |
| US-20240309011-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, TNNC1 | USP30 2511/4885HTT 1314/4885SMN1; SMN2 101/4885 |
| US-20220306642-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, TNNC1 | USP30 2511/4885HTT 1314/4885SMN1; SMN2 101/4885 |
| US-20240132498-A1 | CRYSTALLINE FORMS OF 5-(3,4-DIFLUOROBENZYL)-8-((1R,4R)-4-METHYLCYCLOHEXYL)-6,9-DIOXO-2,5,8-TRIAZASPIRO[3.5]NONANE-2-CARBALDEHYDE | UACA, TUBA3C, CA5B | USP30 2792/4885HTT 2660/4885SMN1; SMN2 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.